Statins in bacteremia, sepsis and pneumonia: Have we found the holy grail?

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 3, Issue 3, 2009, Pages 167-176

  Stamatogiannis, Nikos ^a   Makris, Demosthenes ^a   Zakynthinos, Epaminondas ^a  

^a UNIVERSITY OF THESSALY   (Greece)

Author keywords

Pneumonia; Sepsis; Septic shock; Statins

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CHOLESTEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HEME OXYGENASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; MEVALONIC ACID; MEVINOLIN; PLACEBO; SIMVASTATIN;

ANTIINFLAMMATORY ACTIVITY; BACTEREMIA; CHOLESTEROL BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CYTOKINE PRODUCTION; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; ENZYME ACTIVITY; ENZYME INHIBITION; GRAM NEGATIVE BACTERIUM; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; INFLUENZA; LIVER DYSFUNCTION; LIVER FUNCTION; LOW DRUG DOSE; MORTALITY; MYALGIA; MYOPATHY; MYOSITIS; OXIDATIVE STRESS; PLEIOTROPY; PNEUMONIA; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK REDUCTION; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; THORAX RADIOGRAPHY; TREATMENT OUTCOME; VAGUS NERVE STIMULATION;

ANTI-INFLAMMATORY AGENTS; BACTEREMIA; CLINICAL TRIALS AS TOPIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PATENTS AS TOPIC; PNEUMONIA;

EID: 70350784300     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221309789257469     Document Type: Review

References (95)

1. Sheffield MC. Multiple effects of statins in non-lipid disease states. US Pharm 2004; 6: 38-54.
2. La Rosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials. JAMA 1999; 282: 2340-2346.
3. Randomised Trial of Cholesterol Lowering in 4444 Patients with Coronary Heart Disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
4. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: The Long- Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. N Engl J Med 1998; 339 (19): 1349-1357.
5. MRC/BHF Heart Protection Study of Cholesterol lowering with simvastatin in 20563 high-risk individuals. A randomized placebocontrolled trial. Lancet 2002; 360: 7-22.
6. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-1009.
7. Serruys PW, Pim de Feyter, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial. JAMA 2002; 287: 3215-3522.
8. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333 (20): 1301-1307.
9. Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackman DG. Statins and sepsis: Multiple modifications at multiple levels. Lancet Infect Dis 2007; 7: 358-368.
10. Majumdar SR, McAlister FA, Eurich DT, Padwal RS, Marrie TJ. Statins and outcomes in patients admitted to hospital and community acquired pneumonia: Population based prospective cohort study. BMJ 2006; 333: 999.
11. HMG-CoA reductase. Wikipedia the free encyclopedia.
12. Roitelman J, Olender EH, Bar-Nun S, Dunn WA, Simoni RD. Immunological evidence for 8 spans in the membrane domain of 3-Hydroxy-3-Methylglutaryl coenzyme A reductase: Implication for enzyme degradation in the endoplasmic reticulum. J Cell Biol 1992; 117: 959-973.
13. Merx MW, Weber C. Statins in the intensive care unit. Curr Opin Crit Care 2006; 12: 309-314.
14. Liao JK. Isoprenoids as mediator of the biological effects of statins. Clin Invest 2002; 110: 285-288.
15. Klag MJ, Ford DE, Mead LA, et al. Serum cholesterol in young men and subsequent cardiovascular disease. N Engl J Med 1993; 328(5): 313-318.
16. Chan K, Oza A, Siu L. The statins as anticancer agents. Clin Cancer Res 2003; 9(1): 10-19.
17. Collins R, Peto R, Armitage J. The MRC/BHF Heart Protection Study: Preliminary results. Int J Clin Pract 2002; 56: 53-56.
18. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993; 87: 1781- 1791.
19. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early reccurent ischemic events in acute coronary syndromes. The MIRACL study: A randomized controlled trial. JAMA 2001; 285: 1711-1718.
20. Almuti K, Rimawi R, Spevack D, Ostfeld RJ. Effects of statins beyond lipid lowering: Potential for clinical benefits. Int J Cardiol 2006; 109: 7-15.
21. Ross R. Atherosclerosis an inflammatory disease. N Engl J Med 1999; 340: 115-126.
22. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999; 100: 230-235.
23. Albert MA, Danielson E, Rifai N, Ridker PM, PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study. JAMA 2001; 286: 64-70.
24. Laufs U, La Fata J, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-1135.
25. Van der Wal AC, Becker AE, Van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant morphology. Circulation 1994; 89: 36-44.
26. Davies M, Richardson P, Woolf N. Risk of thrombosis in human atherosclerotic plaques: The role of extracellular lipid, macrophages, and smooth muscle cell content. Br Heart J 1993; 69: 377-381.
27. Steffens S, Mach F. Drug Insight: Immunomodulatory effects of statins-potential benefits for renal patients? Nat Clin Pract Nephrol 2006; 2(7): 378-387.
28. Veillard NR, Mach F. Statins: The new aspirin? Cell Mol Life Sci 2002; 59: 1771-1786.
29. Wennerberg K, Rossman KL, Der CJ. The Ras super family at a glance. J Cell Sci 2005; 118: 843-846.
30. Marti G, Duez H, Blanquart C, et al. Statin induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-1. J Clin Invest 2001; 107: 1423-1432.
31. Delerive P, De Bosscher K, Besnard S, et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-KappaB and AP-1. J Biol Chem 1999; 274: 32048-32054.
32. Ortego M, Bustos C, Hernandez-Presa MA, et al. Atorvastatin reduces NF-KappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999; 147: 253-261.
33. Zelvyte I, Dominaitiene R, Crisby M, Janciauskiene S. Modulation of inflammatory mediators and PPRgamma and NFKappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res 2002; 45: 147-54.
34. Hanada T, Yoshimura A. Regulation of cytokine signalling and inflammation. Cytokine Growth Factor Rev 2002; 13: 413-421.
35. Lane, H., O'Reilly, T.: US20090012105 (2009).
36. Weant KA, Cook AM. Potential roles for Statins in Critically Ill patients. Pharmacotherapy 2007; 27(9): 1279-1296.
37. Marshall JC. Sepsis: Current status, future prospects. Curr Opin Crit Care 2004; 10: 250-264.
38. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999; 340: 207-214.
39. Martin CP, Talbert RL, Burgess DS, Peters JL. Effectiveness of Statins in reducing the rate of Severe Sepsis: A Retrospective Evaluation. Pharmacotherapy 2007; 27(1): 20-26.
40. Almog Y, Shefer A, Novack V, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 2004; 110(7): 880-885.
41. Forrest, M.J., DeMartino, J. A., Flicker, M. R., Melian, A., Kanwar, S., Romano, G. J.: US20080194548 (2008).
42. Wang HR, Li JJ, Huang CX, Jiang H. Fluvastatin inhibits the expression of tumor necrosis factor -alpha and activation of nuclear factor-kappab in human endothelial cells stimulated by C-reactive protein. Clin Chim Acta 2005; 353: 53-60.
43. Grip O, Janciauskiene S, Lindgren S. Atorvastatin activates PPARgamma and attenuates the inflammatory response in human monocytes. Inflamm Res 2002; 51: 58-62.
44. Matsumoto M, Einhaus D, Gold ES, Aderem A. Simvastatin augments lipopolysaccharide-induced proinflammatory responses in macrophages by differential regulation of the c-Fos and c-Jun transcription factors. J Immunol 2004; 172: 7377-7384.
45. Ando H, Takamura T, Ota T, Nagai Y, Kobayashi K. Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J Pharmacol Exp Ther 2000; 294: 1043-1046.
46. Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999; 353: 983-984.
47. Pleiner J, Schaller G, Mittermayer F, et al. Simvastatin prevents vascular hyporeactivity during inflammation. Circulation 2004; 110: 3349-3354.
48. Diomede L, Albani D, Sottocorno M, et al. in vivo Anti-inflammatory effects of statins are mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol 2001; 21: 1327-1332.
49. Kothe H, Dalhoff K, Rupp J, et al. Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation 2000; 101: 1760-1763.
50. Steiner S, Speidl WS, Pleiner J, et al. Simvastatin blunts endotoxin - induced tissue factor in vivo. Circulation 2005; 111: 1841-1846.
51. Romano M, Diomede L, Sironi M, et al. Inhibition of monocyte chemotactic protein -1 synthase by statins. Lab Invest 2000; 80: 1095-1100.
52. Veillard NR, Braunersreuther V, Arnaud C, et al. Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis 2006; 188: 51-58.
53. Pruefer D, Scalia R, Lefer AM. Simvastatin inhibits leukocyte - endothelial interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler Thromb Vasc Biol 1999; 19: 2894-2900.
54. Weber C, Erl W, Weber KS, Weber PC. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997; 30: 1212-1217.
55. Yoshida M, Sawada T, Ishii H, et al. HMG-CoA reductase inhibitor modulates monocyte endothelial cell interaction under physiological flow conditions in vitro: Involvement of Rho GTPase-dependent mechanism. Arterioscler Thromb Vasc Biol 2001; 21: 1165-1171.
56. Kallen J, Welzenbach K, Ramage P, et al. Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I -domain. J Mol Biol 1999; 292: 1-9.
57. Weitz- Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7: 687-692.
58. Kwak B, Mullhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6: 1399-1302.
59. Jakobson JR, Bernard JW, Grigoryev DN, Ma SF, Tuder RM, Garcia JG. Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol 2005; 288: 1026-1032.
60. Bateman RM, Sharpe MD, Ellis CG. Bench-to- bedside review; microvascular dysfunction in sepsis-hemodynamics oxygen transport, and nitric oxide. Crit Care 2003; 7: 359-373.
61. Guilford, F. T.: US20090047340 (2009).
62. Huang KC, Chen CW, Chen JC, Lin WW. HMG-CoA reductase inhibitors inhibit inducible nitric oxide synthase gene expression in macrophages. J Biomed Sci 2003; 10: 53-60.
63. Giusti-Paiva A, Martinez MR, Felix JV, et al. Simvastatin decreases nitric oxide overproduction and reverts the impaired vascular responsiveness induced by endotoxic shock in rats. Shock 2004; 21: 271-275.
64. Pruefer D, Makowski J, Schnell M, et al. Simvastatin inhibits inflammatory properties of Staphyloccocus aureus alpha-toxin. Circulation 2002; 106: 2104-2110.
65. Brouard S, Otterbein LE, Anrather J, et al. Carbon monoxide generated by heme oxygenase 1 suppresses endothelial cell apoptosis. J Exp Med 2000; 192: 1015-1026.
66. Morita T, Mitsialis SA, Koike H, Liu Y, Kourembanas S. Carbon monoxide controls the proliferation of hypoxic vascular smooth muscle cells. J Biol Chem 1997; 272: 32804-32809.
67. Otterbein LE, Bach FH, Alam J, et al. Carbon monoxide has antiinflammatory effects involving the mitogen-activated protein Kinase pathway. Nat Med 2000; 6: 422-428.
68. Otterbein LE, Mantell LL, Choi AM. Carbon monoxide provides protection against hyperoxic lung injury. Am J Physiol 1999; 276: L688-L694.
69. Song R, Mahidhara RS, Liu F, Ning W, Otterbein LE, Choi AM. Carbon monoxide inhibits human airway smooth muscle cell proliferation via mitogen activated protein kinase pathway. Am J Resp Cell Moll Biol 2002; 27: 603-610.
70. Lee TS, Chang CC, Zhu Y, Shyy JY. Simvastatin induces heme oxygenase -1: A novel mechanism of vessel protection. Circulation 2004; 110: 1296-1302.
71. Grosser N, Hemmerle A, Berndt G, et al. The antioxidant defense protein heme oxygenase-1 is a novel target for statins in endothelial cells. Free Radic Biol Med 2004; 37: 2064-2071.
72. Levi M. Platelets. Crit Care Med 2005; 33: (Suppl 12): S523-S525.
73. Shi J, Wang J, Zheng H, et al. Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide -dependent mechanism and counteract tumor necrosis factor alpha induced thrombomodulin doenregulation. Blood Coagul Fibrinolysis 2003; 14: 575-585.
74. Dichtl W, Dulak J, Frick M, et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003; 23: 58-63.
75. Bourcier T, Libby P. HMG-CoA reductase inhibitors reduces plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol 2000; 20: 556-562.
76. Lobo SM, Lobo FR, Bota DP, et al. C-reactive protein levels correlate with mortality and organ failure in critically ill patients. Chest 2003; 123: 2043-2049.
77. Birnbaum, Y.: US20080051417 (2008).
78. Welzig CM, Shin DG, Park HJ, et al. Lipid lowering by pravastatin increases parasympathetic modulation of heart rate: Galpha(i2), a possible molecular marker for parasympathetic responsiveness. Circulation 2003; 108: 2743 -2746
79. Tracey KH. Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest 2007; 117: 289-296.
80. Werdan K, Schmidt H, Ebelt H, et al. Impaired regulation of cardiac function in sepsis, SIRS and MODS. Can J Physiol Pharmacol 2009; 87: 266-274.
81. Kopterides P, Falagas ME. Statins for sepsis: a critical and updated review. Clin Microbiol Infect 2009; 15(4): 325-334.
82. Thomsen RW, Hundborg HH, Johnsen SP, et al. Statin use and mortality within 180 days after bacteremia: A population- based cohort study. Crit Care Med 2006; 34: 1080-1086.
83. Kruger P, Fitzsimmons K, Cook D, Jones M, Nimmo G. Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med 2006; 32: 75-79.
84. Liappis AP, Kan VL, Rochester CG, Simon GL. The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 2001; 33: 1352-1357.
85. Hackman DG, Mamdani M, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: A population- based cohort analysis. Lancet 2006; 367: 413-418.
86. Schmidt H, Hennen R, Keller A, et al. Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome. Intensive Care Med 2006; 32: 1248-1251.
87. Mortensen EM, Restrepo MI, Anzueto A, Pugh J. The effect of prior statin use on 30-day mortality for patients hospitalized with community acquired pneumonia (online exclusive article). Respir Res 2005; 25: 82.
88. Schlienger RG, Fedson DS, Jick SS, Jick H, Meier CR. Statins and the Risk of Pneumonia: A population-based, nested case-control study. Pharmacotherapy 2007; (3): 325-332.
89. Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007; 131: 1006-1012.
90. Gautret P, Yong W, Soula G, et al. Incidence of Hajj-associated febrile cough episodes among French pilgrims: A prospective cohort study on the influence of statin use and risk factors. Clin Microbiol Infect 2009; 15: 335-340.
91. Chalmers JD, Singanayagam A, Murray MP, Hill AT. Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med. 2008; 121(11): 1002-1007.
92. Mortensen EM, Pugh MJ, Copeland LA, et al. Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. Eur Respir J 2008; 31: 611-617.
93. Gupta R, Plantinga LC, Fink NE, et al. Statin use and hospitalization for sepsis in patients with chronic kidney disease. JAMA 2007; 297: 1455-1464.
94. Soyseth V, Brekke PH, Smith P, Omland T. Statin use is associated with reduced mortality in COPD. Eur Respir J 2007; 29: 279-283.
95. Van der Garde EM, Hak E, Souverein PC, Hoes AW, Van den Bosch JM, Leufkens HG. Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax 2006; 61: 957-961.